- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
强势上涨过程中，可逢低买进，暂不考虑做空。
- 中期趋势：
上涨趋势有所减缓，可适量高抛低吸。
- 长期趋势：
已有9家主力机构披露2025-12-31报告期持股数据，持仓量总计63.96万股，占流通A股0.11%
- 波段诊断：
-
技术面诊股
诊断结果：7.2技术面打败了58%的股票
技术面评分前10的股票
近期的平均成本为36.18元。多头行情中，上涨趋势有所减缓，可适量做高抛低吸。
平均成本
近期的平均成本为36.18元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"36.18","date":1769327479,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势跑赢大盘，跑输行业平均水平。
[{"date":"2026.01.26","stock":"0.00","trade":"0.66","ind":"-0.85"},{"date":"2026.01.23","stock":"1.45","trade":"1.43","ind":"0.79"},{"date":"2026.01.22","stock":"0.08","trade":"-0.07","ind":"0.50"},{"date":"2026.01.21","stock":"-0.22","trade":"0.37","ind":"0.70"},{"date":"2026.01.20","stock":"0.00","trade":"-0.41","ind":"-0.97"},{"date":"2026.01.19","stock":"0.20","trade":"0.41","ind":"0.09"},{"date":"2026.01.16","stock":"-0.64","trade":"-0.81","ind":"-0.18"},{"date":"2026.01.15","stock":"-1.12","trade":"-1.14","ind":"0.41"},{"date":"2026.01.14","stock":"-0.74","trade":"-0.56","ind":"0.56"},{"date":"2026.01.13","stock":"1.13","trade":"1.21","ind":"-1.37"},{"date":"2026.01.12","stock":"-0.74","trade":"0.28","ind":"1.75"},{"date":"2026.01.09","stock":"0.91","trade":"1.86","ind":"1.15"},{"date":"2026.01.08","stock":"-1.47","trade":"1.15","ind":"-0.51"},{"date":"2026.01.07","stock":"3.17","trade":"0.44","ind":"0.06"},{"date":"2026.01.06","stock":"1.45","trade":"0.51","ind":"1.40"},{"date":"2026.01.05","stock":"2.00","trade":"3.09","ind":"2.24"},{"date":"2025.12.31","stock":"-0.20","trade":"-0.07","ind":"-0.58"},{"date":"2025.12.30","stock":"-0.29","trade":"-0.48","ind":"0.49"},{"date":"2025.12.29","stock":"-1.06","trade":"-1.13","ind":"-0.49"},{"date":"2025.12.26","stock":"-0.43","trade":"-0.41","ind":"0.54"},{"date":"2025.12.25","stock":"0.20","trade":"0.35","ind":"0.33"}]
丽珠集团,深证成指,化学制药指数
压力支撑
该股压力位为36.07元，支撑位为35.68元。
[{"text":"\u538b\u529b\u4f4d","value":"36.07","date":1769356800,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"35.68","date":1769356800,"color":"0x0b52a1"}]
多空趋势
多头行情中，上涨趋势有所减缓，可适量做高抛低吸。
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：3.0资金面打败了32%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金流出较多，不建议投资者关注该行业的个股。
更新时间：01月26日 17:20
| 机构今日流向(万元) | -1543.05 | 机构5日流向(万元) | -7070.78 |
| 机构10日流向(万元) | -17834.28 | 机构20日流向(万元) | -19976.26 |
机构持仓
2025-12-31 与 2025-06-30 相比，主力机构持仓量减少32412.61万股，其中基金数没有增加，主力净减仓452家，请投资者中长期谨慎为宜。
截止2025-12-31，共9家主力机构（基金9家），持仓量总计63.96万股，占流通A股0.11%
其中，基金持仓与2025-06-30相比：
增仓：3家 ，增持 14.75万股
减仓：3家 ，减持 4.87万股
新出现在主力名单中：3家 ，持有16.92万股
从主力名单中消失：455家 ，原持有32439.41万股
其中，基金持仓与2025-06-30相比：
增仓：3家 ，增持 14.75万股
减仓：3家 ，减持 4.87万股
新出现在主力名单中：3家 ，持有16.92万股
从主力名单中消失：455家 ，原持有32439.41万股
消息面诊股
诊断结果：5.5消息面打败了12%的股票
今日有利好新闻的公司
近期该股消息面总体多空平衡，没有较强的利好或利空趋势。
更多>>个股资讯
- 行业周报|化学制药指数涨1.73%, 跑赢上证指数
2026-01-23 - 丽珠集团：1月22日获融资买入2678.18万元
2026-01-23 - 【机构调研记录】宝盈基金调研丽珠集团、ST绝味等3
2026-01-23 - 【私募调研记录】明汯投资调研丽珠集团
2026-01-23 - 丽珠集团：丽珠生物拥有三大业务板块
2026-01-22 - 丽珠集团：公司在出海战略上采取“双轨并行”的核心布
2026-01-22 - 丽珠集团获15家机构调研：H001是一款口服的直接
2026-01-22 - 基金最新动向：走访这25家公司
2026-01-22 - 基金调研丨宝盈基金调研丽珠集团
2026-01-22 - 丽珠集团：1月20日获融资买入1251.48万元
2026-01-21
消息列表
| 一般消息 | 重大事项 | 关联交易 | 2025-12-31 |
| 一般消息 | 高管变动 | 因个人原因 | 2025-12-30 |
| 一般消息 | 高管变动 | 任期满六年 | 2025-12-10 |
| 一般消息 | 股东大会 | 临时股东大会 | 2025-11-11 |
| 一般消息 | 重大事项 | 关联交易 | 2025-08-23 |
| 一般消息 | 分红转增 | 不分配不转增 | 2025-08-21 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2025-08-20 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2025-06-30 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2025-04-23 |
| 一般消息 | 高管变动 | 因个人发展原因 | 2025-03-31 |
| 利好 | 分红转增 | 10派11元(含税) | 2025-03-27 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 2条 | 0条 | 2条 |
| 利空 | 0条 | 0条 | 0条 |
行业面诊股
诊断结果：7.6行业面打败了82%的股票
化学制药行业最新资金流向
近10日来该行业走势不明显，明显跑赢大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势不明显，明显跑赢大盘。
[{"date":"2026.01.26","price":"-0.85","value":"0.66"},{"date":"2026.01.23","price":"0.79","value":"1.43"},{"date":"2026.01.22","price":"0.50","value":"-0.07"},{"date":"2026.01.21","price":"0.70","value":"0.37"},{"date":"2026.01.20","price":"-0.97","value":"-0.41"},{"date":"2026.01.19","price":"0.09","value":"0.41"},{"date":"2026.01.16","price":"-0.18","value":"-0.81"},{"date":"2026.01.15","price":"0.41","value":"-1.14"},{"date":"2026.01.14","price":"0.56","value":"-0.56"},{"date":"2026.01.13","price":"-1.37","value":"1.21"},{"date":"2026.01.12","price":"1.75","value":"0.28"},{"date":"2026.01.09","price":"1.15","value":"1.86"},{"date":"2026.01.08","price":"-0.51","value":"1.15"},{"date":"2026.01.07","price":"0.06","value":"0.44"},{"date":"2026.01.06","price":"1.40","value":"0.51"},{"date":"2026.01.05","price":"2.24","value":"3.09"},{"date":"2025.12.31","price":"-0.58","value":"-0.07"},{"date":"2025.12.30","price":"0.49","value":"-0.48"},{"date":"2025.12.29","price":"-0.49","value":"-1.13"},{"date":"2025.12.26","price":"0.54","value":"-0.41"},{"date":"2025.12.25","price":"0.33","value":"0.35"}]
深证成指,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 必贝特 | 85.12% | 5.48% | 5.6分 |
| 2 | 键凯科技 | 30.48% | 3.44% | 6.4分 |
| 3 | 前沿生物 | 30.44% | -0.12% | 4.9分 |
| 4 | 多瑞医药 | 29.46% | 5.98% | 5.8分 |
| 5 | 奥锐特 | 28.28% | -5.22% | 5.8分 |
| 6 | - | 25.30% | 8.79% | 分 |
| 8 | 尔康制药 | 24.72% | 10.58% | 6.6分 |
| 10 | 华邦健康 | 20.74% | 5.76% | 6.7分 |
| 12 | 微芯生物 | 18.30% | 0.85% | 5.8分 |
| 14 | 普洛药业 | 17.40% | 6.26% | 6.6分 |
| 16 | 汉商集团 | 17.26% | 5.29% | 6.5分 |
| 18 | 悦康药业 | 16.45% | -0.74% | 5.4分 |
| 20 | 誉衡药业 | 15.65% | 12.77% | 6.8分 |
| 22 | 国邦医药 | 15.05% | 10.36% | 5.8分 |
| 24 | 花园生物 | 14.92% | 2.03% | 5.7分 |
| 26 | 福元医药 | 13.83% | 1.82% | 5.5分 |
| 28 | 美诺华 | 13.36% | 9.34% | 6.4分 |
| 30 | 汇宇制药 | 12.24% | -2.12% | 4.8分 |
| 32 | 海森药业 | 11.63% | 4.21% | 6.2分 |
| 34 | 南新制药 | 11.25% | 4.60% | 5.8分 |
| 36 | 广生堂 | 10.95% | 20.12% | 5.1分 |
| 38 | 鲁抗医药 | 10.83% | 10.24% | 5.9分 |
| 40 | 拓新药业 | 10.02% | 7.03% | 4.8分 |
| 42 | 仟源医药 | 9.91% | 3.23% | 5.5分 |
| 44 | 本立科技 | 9.75% | 2.15% | 5.6分 |
| 46 | 西点药业 | 9.67% | 2.84% | 6.3分 |
| 48 | - | 9.41% | 4.44% | 分 |
| 50 | 力生制药 | 9.21% | 2.71% | 6.7分 |
| 52 | 盟科药业 | 8.94% | 3.55% | 5.8分 |
| 54 | 润都股份 | 8.39% | -2.61% | 5.9分 |
| 56 | 小方制药 | 8.16% | 3.46% | 6.6分 |
| 58 | 复旦张江 | 8.12% | 4.14% | 6.1分 |
| 60 | 易明医药 | 7.96% | 1.99% | 5.5分 |
| 62 | 海正药业 | 7.78% | 3.89% | 6.4分 |
| 64 | 赛分科技 | 7.50% | 2.86% | 6.7分 |
| 66 | 共同药业 | 7.45% | 1.07% | 5.4分 |
| 68 | 溢多利 | 7.29% | 2.41% | 5.7分 |
| 70 | 金陵药业 | 6.80% | 1.39% | 6.2分 |
| 72 | 华仁药业 | 6.54% | 5.23% | 6.4分 |
| 74 | 兴齐眼药 | 5.75% | -8.96% | 5.3分 |
| 76 | 辰欣药业 | 5.61% | 5.32% | 5.6分 |
| 78 | 科伦药业 | 5.31% | -1.29% | 5.1分 |
| 80 | 健友股份 | 5.09% | 2.43% | 6.1分 |
| 82 | 福安药业 | 4.87% | 4.18% | 6.1分 |
| 84 | 海翔药业 | 4.75% | -2.14% | 3.8分 |
| 86 | 神奇制药 | 4.65% | 4.48% | 6.5分 |
| 88 | 九典制药 | 4.48% | 2.62% | 5.7分 |
| 90 | 海普瑞 | 4.41% | 3.21% | 6.1分 |
| 92 | - | 4.34% | 2.33% | 分 |
| 94 | 亚太药业 | 4.24% | 5.22% | 5.9分 |
| 96 | 奥翔药业 | 4.16% | 0.70% | 5.5分 |
| 98 | 丰原药业 | 4.02% | 2.91% | 6.3分 |
| 100 | 东诚药业 | 4.01% | -1.04% | 5.1分 |
| 102 | 罗欣药业 | 3.87% | 3.45% | 6.1分 |
| 104 | 健康元 | 3.57% | 2.10% | 6.1分 |
| 106 | 东北制药 | 3.55% | 4.73% | 6.4分 |
| 108 | 民生健康 | 3.37% | 0.06% | 5.0分 |
| 110 | 立方制药 | 3.36% | 2.64% | 6.0分 |
| 112 | ST复华 | 3.19% | 4.76% | 5.3分 |
| 114 | *ST景峰 | 2.81% | -2.54% | 5.0分 |
| 116 | 津药药业 | 2.61% | 2.37% | 6.2分 |
| 118 | 奥赛康 | 1.98% | -5.29% | 4.6分 |
| 120 | 莎普爱思 | 1.69% | 1.56% | 5.4分 |
| 122 | 舒泰神 | 1.37% | 0.32% | 4.6分 |
| 124 | 华纳药厂 | 0.67% | 4.31% | 5.3分 |
| 126 | 迪哲医药 | 0.39% | -11.35% | 5.1分 |
| 128 | 天新药业 | 0.00% | -0.15% | 5.8分 |
| 130 | 莱美药业 | -0.57% | 7.19% | 4.3分 |
| 132 | 华海药业 | -0.87% | 0.65% | 4.5分 |
| 134 | 博瑞医药 | -2.17% | -2.06% | 5.0分 |
| 136 | ST诺泰 | -2.87% | -0.13% | 4.2分 |
| 138 | 德展健康 | -2.99% | -1.77% | 4.2分 |
| 140 | 河化股份 | -3.27% | 0.27% | 5.7分 |
| 142 | 恩华药业 | -4.73% | 0.37% | 4.1分 |
| 144 | 艾力斯 | -5.34% | -0.79% | 5.0分 |
| 146 | 海创药业 | -6.32% | -4.28% | 4.3分 |
| 148 | *ST三圣 | -9.17% | -1.62% | 4.1分 |
| 150 | 海南海药 | -12.22% | 2.60% | 4.7分 |
| 152 | 泽璟制药 | -13.34% | -5.44% | 4.1分 |
| 154 | 常山药业 | -14.70% | -1.86% | 3.6分 |
| 156 | 信立泰 | -16.77% | -7.54% | 4.9分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2025-09-30 ]公司经营
盈利能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 15/217 ， 36/217。
[{"date":"2025-09-30","value":"12.61","vol":"1.51"},{"date":"2025-06-30","value":"9.30","vol":"1.23"},{"date":"2025-03-31","value":"4.54","vol":"-0.14"},{"date":"2024-12-31","value":"14.77","vol":"19.62"},{"date":"2024-09-30","value":"11.86","vol":"4.62"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
12.61 | 9.30 | 4.54 | 14.77 | 11.86 |
| 行业(%) | 1.51 | 1.23 | -0.14 | 19.62 | 4.62 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"66.39","vol":"49.36"},{"date":"2025-06-30","value":"66.02","vol":"49.33"},{"date":"2025-03-31","value":"64.96","vol":"49.14"},{"date":"2024-12-31","value":"65.45","vol":"50.78"},{"date":"2024-09-30","value":"65.81","vol":"50.61"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
66.39 | 66.02 | 64.96 | 65.45 | 65.81 |
| 行业(%) | 49.36 | 49.33 | 49.14 | 50.78 | 50.61 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 63/217 ， 65/217。
[{"date":"2025-09-30","value":"0.38","vol":"142.98"},{"date":"2025-06-30","value":"-0.17","vol":"79.25"},{"date":"2025-03-31","value":"-1.92","vol":"-0.67"},{"date":"2024-12-31","value":"-4.97","vol":"18.07"},{"date":"2024-09-30","value":"-5.94","vol":"45.94"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
0.38 | -0.17 | -1.92 | -4.97 | -5.94 |
| 行业(%) | 142.98 | 79.25 | -0.67 | 18.07 | 45.94 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"4.86","vol":"-3.26"},{"date":"2025-06-30","value":"9.40","vol":"58.57"},{"date":"2025-03-31","value":"4.75","vol":"-11.22"},{"date":"2024-12-31","value":"5.50","vol":"-22.02"},{"date":"2024-09-30","value":"4.44","vol":"-34.66"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
4.86 | 9.40 | 4.75 | 5.50 | 4.44 |
| 行业(%) | -3.26 | 58.57 | -11.22 | -22.02 | -34.66 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 42/217 ， 67/217。
[{"date":"2025-09-30","value":"0.37","vol":"0.31"},{"date":"2025-06-30","value":"0.26","vol":"0.21"},{"date":"2025-03-31","value":"0.13","vol":"0.10"},{"date":"2024-12-31","value":"0.48","vol":"0.43"},{"date":"2024-09-30","value":"0.36","vol":"0.33"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.37 | 0.26 | 0.13 | 0.48 | 0.36 |
| 行业(次) | 0.31 | 0.21 | 0.10 | 0.43 | 0.33 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"1.68","vol":"1.94"},{"date":"2025-06-30","value":"1.15","vol":"1.30"},{"date":"2025-03-31","value":"0.57","vol":"0.66"},{"date":"2024-12-31","value":"2.01","vol":"3.19"},{"date":"2024-09-30","value":"1.53","vol":"2.12"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
1.68 | 1.15 | 0.57 | 2.01 | 1.53 |
| 行业(次) | 1.94 | 1.30 | 0.66 | 3.19 | 2.12 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：数据暂时不全，请后续关注
[{"date":"2025-09-30","value":"29.48","vol":"4.43"},{"date":"2025-06-30","value":"31.13","vol":"2.74"},{"date":"2025-03-31","value":"22.79","vol":"-26.98"},{"date":"2024-12-31","value":"24.57","vol":"-373.99"},{"date":"2024-09-30","value":"27.79","vol":"-9.47"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 29.48 | 31.13 | 22.79 | 24.57 | 27.79 |
| 行业 | 4.43 | 2.74 | -26.98 | -373.99 | -9.47 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"","vol":"0.00"},{"date":"2025-06-30","value":"1.23","vol":"1.73"},{"date":"2025-03-31","value":"","vol":"0.00"},{"date":"2024-12-31","value":"0.91","vol":"2.00"},{"date":"2024-09-30","value":"","vol":"0.00"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | - | 1.23 | - | 0.91 | - |
| 行业 | 0.00 | 1.73 | 0.00 | 2.00 | 0.00 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 16/217 ， 86/217。
[{"date":"2025-09-30","value":"2.25","vol":"3.50"},{"date":"2025-06-30","value":"2.19","vol":"3.69"},{"date":"2025-03-31","value":"2.28","vol":"3.61"},{"date":"2024-12-31","value":"2.15","vol":"3.36"},{"date":"2024-09-30","value":"1.84","vol":"3.67"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 流动比率 |
2.25 | 2.19 | 2.28 | 2.15 | 1.84 |
| 行业 | 3.50 | 3.69 | 3.61 | 3.36 | 3.67 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"1.95","vol":"2.75"},{"date":"2025-06-30","value":"1.90","vol":"2.90"},{"date":"2025-03-31","value":"1.97","vol":"2.83"},{"date":"2024-12-31","value":"1.86","vol":"2.65"},{"date":"2024-09-30","value":"1.58","vol":"2.93"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 速动比率 |
1.95 | 1.90 | 1.97 | 1.86 | 1.58 |
| 行业 | 2.75 | 2.90 | 2.83 | 2.65 | 2.93 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 48/217 ， 55/217。
[{"date":"2025-09-30","value":"37.37","vol":"33.63"},{"date":"2025-06-30","value":"38.26","vol":"33.66"},{"date":"2025-03-31","value":"37.21","vol":"33.90"},{"date":"2024-12-31","value":"39.05","vol":"34.07"},{"date":"2024-09-30","value":"40.04","vol":"32.87"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
37.37 | 38.26 | 37.21 | 39.05 | 40.04 |
| 行业(%) | 33.63 | 33.66 | 33.90 | 34.07 | 32.87 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"0.66","vol":"0.94"},{"date":"2025-06-30","value":"0.68","vol":"0.88"},{"date":"2025-03-31","value":"0.64","vol":"1.47"},{"date":"2024-12-31","value":"0.69","vol":"0.84"},{"date":"2024-09-30","value":"0.70","vol":"0.73"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.66 | 0.68 | 0.64 | 0.69 | 0.70 |
| 行业(%) | 0.94 | 0.88 | 1.47 | 0.84 | 0.73 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以买入为主，认为该股票非常值得关注。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 国泰海通证券 | 2025-11-18 | 买入 | |
| 中信建投证券 | 2025-11-06 | 买入 | |
| 国信证券 | 2025-11-03 | 买入 | |
| 甬兴证券 | 2025-11-03 | 买入 | |
| 东海证券 | 2025-10-31 | 买入 |
机构预测
机构预测该股2025年每股收益与前一年相同，长期投资价值一般。
[{"date":"2021","yellowRectValue":"17.76","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"19.09","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"19.54","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"20.61","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"22.57","blueLineValue":"2.49","type":"YC"}]